In addition, this study indicated that the lower expression of ANXA2 protein might also activate asthma, ECM-receptor interaction, leishmaniasis, malaria, and renin-angiotensin system (RAS) pathways, all of which might potentially regulate HCM treatment. This evidence concerns the gene ANXA2 and asthma.